Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Equivalents (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Cash & Equivalents data on record, last reported at $64.8 million in Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 88.74% year-over-year to $64.8 million; the TTM value through Sep 2023 reached $64.8 million, down 88.74%, while the annual FY2022 figure was $156.2 million, 161.24% up from the prior year.
  • Cash & Equivalents reached $64.8 million in Q3 2023 per CGEM's latest filing, down from $491.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $611.0 million in Q2 2022 and bottomed at $59.8 million in Q4 2021.
  • Average Cash & Equivalents over 4 years is $308.0 million, with a median of $304.2 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 394.06% in 2022, then crashed 88.74% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $168.2 million in 2020, then tumbled by 64.46% to $59.8 million in 2021, then surged by 161.24% to $156.2 million in 2022, then crashed by 58.47% to $64.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $64.8 million in Q3 2023, $491.8 million in Q2 2023, and $390.7 million in Q1 2023.